Home About UsAims & Objectives Antimicrobial.Resistance Antimicrobial data Bench Protocols Healthcare.Asso.InfecEducational Material News & Updates Meeting & Events Research Activities Useful Links FAQs Contact Us

 

New Recommendations of ESBL detection in Enterobacteriaceae in CLSI 2010

 

In CLSI M100 2010, new revised interpretive criteria for cephalosporins (cefazolin, cefotaxime, ceftazidime, and ceftriaxone) and aztreonam susceptibility were established.  Following evaluation of pharmacokinetics-pharmacodynamics (PK-PD) properties and limited clinical data, and on the basis of dosage regimens the breakpoints are revised.

Cephalosporin

CLSI  M100 S-19 (2009) Sensitive

CLSI M100 S-20 (2010) Sensitive

Cefotaxime

≥23

≥26

Ceftriaxone

≥21

≥23

Ceftazidime

≥18

≥21

CSeftizoxime

≥20

≥21

Aztreonam

≥22

≥21

 When using the new interpretive criteria, routine ESBL testing is no longer necessary before reporting results (e.g. it is no longer necessary to edit results for cephalosporin, aztreonam, or penicillin from susceptible to resistant. However until laboratories implement the new interpretive criteria, ESBL testing should be routinely performed as described previously. ESBL testing may still be useful for epidemiological and infection control purposes.

 

Dr Binish Arif

 

 

 

 

 

 

Copyright @ Antimicrobial Resistance Network 2011, All right reserved

   
Designed & Developed By: Faisal Riaz Malik